How many drugs treat Endometrial carcinoma?

Drug Landscape tracks 5 marketed treatments for Endometrial carcinoma (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/endometrial-carcinoma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Endometrial carcinoma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Endometrial carcinoma (disease) competitive landscape: 5 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

5 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Endometrial carcinoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Megace	MEGESTROL ACETATE	Bristol-Myers Squibb	Progestin	Glucocorticoid receptor	1971-01-01
Endometrin	progesterone	Ferring	Progesterone [EPC]	Corticosteroid-binding globulin, Sodium/nucleoside cotransporter 1, Cation channel sperm-associated protein 1
Progesteron	Progesteron	Minia University		Corticosteroid-binding globulin, Sodium/nucleoside cotransporter 1, Cation channel sperm-associated protein 1
megestrol	megestrol	National Center for Research Resources (NCRR)		Cytochrome P450 2C9, Multidrug resistance protein 1, Glucocorticoid receptor
Depo-Provera	medroxyprogesterone	Pfizer	Progestin	Progesterone receptor	1959-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Bristol-Myers Squibb · 1 drug in Endometrial carcinoma
Ferring · 1 drug in Endometrial carcinoma
Minia University · 1 drug in Endometrial carcinoma
National Center for Research Resources (NCRR) · 1 drug in Endometrial carcinoma
Pfizer · 1 drug in Endometrial carcinoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Endometrial carcinoma:

Cite this brief

Drug Landscape (2026). Endometrial carcinoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/endometrial-carcinoma. Accessed 2026-06-10.

Endometrial carcinoma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing